Good news. I believe this is the second fully-regulatory body compliant phase3 clinical trial started for PSC (on-going norUDCA in Europe is the other one).
Gilead announced last year positive Phase 2 results (see here https://www.gilead.com/news-and-press/press-room/press-releases/2018/11/gilead-announces-positive-phase-2-results-for-gs9674-in-primary-sclerosing-cholangitis-psc-at-the-liver-meeting-2018 )
The new Phase3 clinical trial details:
Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PSC-Phase 3) (PSC-Phase 3)
Sponsor: Gilead Sciences
Estimated Study Start Date: March 2019
Estimated Primary Completion Date: August 2022
Estimated Study Completion Date: August 2022